UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
July 27, 2026
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F ☒
Form 40-F ☐
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 27 July 2026 – On 6 May 2026, Novo Nordisk
initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council
of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This
programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning
4 February 2026.
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares
for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.
Since the announcement 20 July 2026, the following transactions have been made:
Number
of
B
shares
Average
purchase
price
Transaction
value,
DKK
Accumulated, last announcement
10,200,000
3,053,177,399
20 July 2026
195,000
329.69
64,289,125
21 July 2026
190,000
324.17
61,591,795
22 July 2026
190,000
321.63
61,108,864
23 July 2026
190,000
313.46
59,557,220
24 July 2026
195,000
321.25
62,644,500
Accumulated under the programme
11,160,000
3,362,368,903
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 43,104,480 B shares of DKK
0.10 as treasury shares, corresponding to 1.0% of the share capital. The total amount of A and B shares in the company is
4,465,000,000 including treasury shares.
Page 2 of 2
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion
during a 12-month period beginning 4 February 2026. As of 24 July 2026, Novo Nordisk has since 4 February 2026 repurchased a total 25,919,179
B shares at an average share price of DKK 276.33 per B share equal to a transaction value of DKK 7,162,368,893.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark.
Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific
breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800
people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn
and YouTube.
Contacts for further information
Media:
Ambre James-Brown
Liz Skrbkova (US)
+45 3079 9289
+1 609 917 0632
globalmedia@novonordisk.com
USMediaRelations@novonordisk.com
Investors:
Michael Novod
Sina Meyer
+45 3075 6050
+45 3079 6656
nvno@novonordisk.com
azey@novonordisk.com
Max Ung
Christoffer Sho Togo Tullin
+45 3077 6414
+45 3079 1471
mxun@novonordisk.com
cftu@novonordisk.com
Alex Bruce
Mads Berner Bruun
+45 3444 2613
+45 3075 2936
axeu@novonordisk.com
mbbz@novonordisk.com
Ida Schaap Melvold
Frederik Taylor Pitter (US)
+45 3077 5649
+1 609 613 0568
idmg@novonordisk.com
fptr@novonordisk.com
Novo Nordisk A/S
Investor Relations
Novo Allé 1
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
www.novonordisk.com
CVR no: 24 25 67 90
Company
announcement No 44 / 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: July 27, 2026
NOVO NORDISK A/S
Maziar Mike Doustdar
Chief Executive Officer